Back to Results
First PageMeta Content
Medicine / Cancer vaccine / Sirolimus / Ovarian cancer / T helper cell / Mammalian target of rapamycin / Breast cancer treatment / Biology / T cells / Immune system


Protocol I199911: A PHASE I CLINICAL TRIAL OF mTOR INHIBITION WITH SIROLIMUS FOR ENHANCING ALVAC(2)-NY-ESO1(M)/TRICOM VACCINE INDUCED ANTI-TUMOR IMMUNITY IN OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER Kunle Odu
Add to Reading List

Document Date: 2013-12-31 11:43:35

Open Document

File Size: 365,78 KB

Share Result on Facebook

Company

Ph.D. / Persistence Antigen / /

Event

Product Issues / FDA Phase / Product Recall / /

Facility

Roswell Park Cancer Institute / /

MedicalCondition

Ovarian cancer / epithelial ovarian cancer / Vaccinia / durable tumor / cancer / cure Refractory/Persistent Disease / disease / /

MedicalTreatment

surgery / chemotherapy / /

Organization

National Institute of Health / Roswell Park Cancer Institute Buffalo / /

Person

Kunle Odunsi / /

Product

Antigen / I125207 / /

Technology

chemotherapy / /

SocialTag